camrelizumab + apatinib + carboplatin + etoposide

Camrelizumab + apatinib + carboplatin + etoposide is a four-drug combination regimen under investigation for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC). Camrelizumab is a humanized anti-PD‑1 monoclonal antibody that blocks the PD‑1/PD-L1 pathway to enhance T-cell mediated immune responses against tumors. Apatinib is a small molecule tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor 2 (VEGFR2), inhibiting tumor angiogenesis. Carboplatin is a platinum-based chemotherapeutic agent that induces DNA crosslinking and apoptosis in rapidly dividing cells. Etoposide is a topoisomerase II inhibitor that causes DNA strand breaks and cell death in proliferating cancer cells. This combination leverages immunotherapy, antiangiogenic therapy, and cytotoxic chemotherapy to maximize antitumor activity. In recent phase II clinical trials for untreated ES-SCLC, this regimen demonstrated promising efficacy with an objective response rate of 88.9%, median progression-free survival of 7.3 months, and median overall survival of 17.3 months[1][2][3][7]. The most common severe adverse events were neutropenia and anemia[1][7].

Brand names

camrelizumab: AiRuiKa (China)apatinib: Aitan, Rivoceranib (internationally as rivoceranib)carboplatin: Paraplatinetoposide: Toposar, Vepesid

Other names

camrelizumab + apatinib + carboplatin + etoposide